|
Ⅱ級PI 曹文楓
曹文楓,，醫(yī)學(xué)博士，主任醫(yī)師,，碩士生導(dǎo)師�,，F(xiàn)任天津醫(yī)科大學(xué)腫瘤醫(yī)院病理科副主任,，天津市腫瘤研究所II級PI，中國抗癌協(xié)會腫瘤病理專業(yè)委員會常委,，中華醫(yī)學(xué)會病理學(xué)分委會青年委員,，天津市抗癌協(xié)會腫瘤學(xué)分委會委員，抗癌協(xié)會兒童腫瘤病理專業(yè)委員會委員,，天津市醫(yī)學(xué)會泌尿外科分委會,、婦科腫瘤分委會委員，中華醫(yī)學(xué)會天津市病理分會委員,。
2002年畢業(yè)于天津醫(yī)科大學(xué),，獲病理學(xué)碩士學(xué)位。同年起在天津市腫瘤醫(yī)院病理科工作,，從事腫瘤病理及分子病理診斷工作,，側(cè)重于盆腔、泌尿腫瘤病理的診斷和鑒別診斷及分子病理診斷,，較為熟練掌握及應(yīng)用現(xiàn)代分子病理診斷技術(shù)進(jìn)行病理輔助診斷及腫瘤分子分型,。2007年獲腫瘤學(xué)博士學(xué)位,。2005年2月至2006年9月在中國醫(yī)學(xué)科學(xué)院腫瘤研究所分子腫瘤學(xué)國家重點(diǎn)實(shí)驗(yàn)室進(jìn)行博士聯(lián)合培養(yǎng),。
長期從事腫瘤侵襲轉(zhuǎn)移相關(guān)研究，主持國家級科研課題1項(xiàng),，省部級課題2項(xiàng),，市局級課題3項(xiàng)，院級課題2項(xiàng)以及參與多項(xiàng)國家省市級合作項(xiàng)目,，順利完成科研課題7項(xiàng),，鑒定科研成果3項(xiàng)，并先后發(fā)表SCI收錄論文近20篇,，第一作者6篇,，通訊作者7篇，發(fā)表國內(nèi)論著二十余篇,，其中以第一作者發(fā)表中華系列論文4篇,，核心期刊5篇。曾先后被授予天津醫(yī)科大學(xué)優(yōu)秀博士畢業(yè)生,，“十一五”新世紀(jì)人才稱號,。
相關(guān)代表性論著：
(1)Lingmei Li#, Lisha Qi, Tongyuan Qu, Changxu Liu, Lu Cao, Qiujuan Huang, Wangzhao Song, Lingyi Yang,
Hui Qi, Yalei Wang, Bin Gao, Yuhong Guo, Baocun Sun, Bin Meng, Bin Zhang, Wenfeng Cao. Epithelial
splicing regulatory protein 1 inhibits the invasion and metastasis of lung adenocarcinoma.,American
Journal of Pathology,2018
(2) Lingyi Yang#, Lin Zhang#, Qiujuan Huang, Changxu Liu, Lisha Qi, Lingmei Li, Tongyuan Qu,
Yalei Wang, Suxiang Liu, Bin Meng, Baocun Sun, Wenfeng Cao*. Combination of Scoring Criteria and
Whole Exome Sequencing Analysis of Synchronous Endometrial
and Ovarian Carcinomas.,International Journal of Gynecological cancer,2018
(3) Cao, Lu# ; Qi, Lisha; Zhang, Lin; Song, Wangzhao; Yu, Yue; Xu, Cong; Li, Lingmei; Guo,
Yuhong; Yang, Lingyi; Liu, Changxu; Huang, Qiujuan; Wang, Yalei; Sun, Baocun; Meng, Bin; Zhang, Bin* ;
Cao,Wenfeng*.Human nonsense-mediated RNA decay regulates EMT by targeting the TGF-ss signaling pathway
in lung adenocarcinoma, CANCER LETTERS, 2017.9.10, 403: 246~259
(4) Lingyi Yang#, Lin Zhang#, Bin Meng, Lin Sun, Lingmei Li, Lisha Qi, Wangzhao Song, Lu Cao,
Yalei Wang, Yanxue Liu, Suxiang Liu, Baocun Sun, Yixin Liu, Wenfeng Cao*. Int J Clin Exp Pathol ,2016;
9(11):11808-11813
(5) Qi, Lisha# ; Song, Wangzhao; Li, Lingmei; Cao, Lu; Yu, Yue; Song, Chunmin; Wang, Yalei; Zhang, Fei;
Li, Yang; Zhang, Bin* ; Cao, Wenfeng*. FGF4 induces epithelial-mesenchymal transition by inducing
store-operated calcium entry in lung adenocarcinoma. , Oncotarget, 2016.11.8, 7(45): 74015~74030
(6) Qi, Lisha# ; Song, Wangzhao# ; Liu, Zhiyong; Zhao, Xiulan; Cao, Wenfeng*; Sun, Baocun* ,Wnt3a
Promotes the Vasculogenic Mimicry Formation of Colon Cancer via Wnt/beta-Catenin Signaling. , Int J Mol Sci,
2015.8.10, 16(8): 18564 ~ 18579
(7) Li, Lingmei# ; Qi, Lisha# ; Liang, Zhijie; Song, Wangzhao; Liu, Yanxue;Wang, Yalei; Sun, Baocun;
Zhang, Bin* ; Cao, Wenfeng*，Transforming growth factor-beta1 induces EMT by the transactivation of epidermal
growth factor signaling through HA/CD44 in lung and breast cancer cells., Int J Mol Med, 2015.7, 36(1): 113~122
(8) Cao, Wenfeng#* ; Zhang, Bin; Ding, Fang; Zhang, Weiran; Sun, Baocun ;Liu, Zhihua* , Expression of SLP-2
Was Associated with Invasion of Esophageal Squamous Cell Carcinoma , PLOS ONE, 2013.5.8, 8(5)
(9) Cao, Wenfeng# ; Zhang, Bin# ; Li, Jin; Liu, Yanxue; Liu, Zhihua; Sun,Baocun* , SLP-2 overexpression
could serve as a prognostic factor in node positive and HER2 negative breast cancer. , Pathology, 2011.12,
43(7): 713~718
(10) Zhang, Bin# ; Cao, Wenfeng#; Zhang, Fei; Zhang, Lin; Niu, Ruifang;
Niu, Yun; Fu, Li; Hao, Xishan; Cao, Xuchen* , Protein interacting with C alpha kinase 1 (PICK1) is
involved in promoting tumor growth and correlates with poor prognosis of human breast cancer , Cancer
Science, 2010.6, 101(6): 1536~1542
(11) Cao, Wenfeng #*; Liu, Yanxue; Zhang, Hong; Wang, Shuhua; Zhang, Lihua;Zhang, Lianyu; Sun, Baocun,
Expression of LMP-1 and Cyclin D1 protein is correlated with an unfavorable prognosis in nasal type NK/T
cell lymphoma, MOLECULAR MEDICINE REPORTS, 2008.6, 1(3): 363~368
(12) Cao, Wen-feng# ; Zhang, Li-yong; Liu, Ming-bo; Tang, Ping-zhang; Liu,Zhi-hua; Sun, Bao-cun* ,
Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell
carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray , HUMAN PATHOLOGY,
2007.5, 38(5): 747~752
(13) Cao, Wenfeng# ; Zhang, Bin# ; Liu, Yanxue; Li, Hongtao; Zhang, Shiwu;Fu, Li; Niu, Yun; Ning, Liansheng;
Cao, Xuchen; Liu, Zhihua; Sun, Baocun* ,High-level SLP-2 expression and HER-2/neu protein expression are
associated with decreased breast cancer patient survival, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007.9,
128(3): 430~436
.............................................................................................................
金勛,，博士,，博士生導(dǎo)師。現(xiàn)任天津醫(yī)科大學(xué)腫瘤醫(yī)院研究所教授,。
聯(lián)系電話：13821445287,；電子郵件：[email protected]
社會兼職：
NEASC協(xié)會會長; 《Glioma》雜志編委,；中國循環(huán)學(xué)會轉(zhuǎn)化醫(yī)學(xué)專業(yè)委員會腫瘤學(xué)組委員;韓國KSNO轉(zhuǎn)化醫(yī)學(xué)委員會委員；中國溫州醫(yī)科大學(xué)第一附屬醫(yī)院訪問教授,。
研究方向：
膠質(zhì)瘤干細(xì)胞及個(gè)體化膠質(zhì)瘤模型作為個(gè)體化靶向治療的預(yù)前試驗(yàn)?zāi)Ｐ褪悄z質(zhì)瘤治療的大趨勢,。金勛教授在從事膠質(zhì)瘤干細(xì)胞研究10余年的過程中，不僅對腫瘤干細(xì)胞原代培養(yǎng),、提純與移植積累了豐富的實(shí)踐經(jīng)驗(yàn),，而且應(yīng)用膠質(zhì)瘤干細(xì)胞先后構(gòu)建過高侵襲性膠質(zhì)瘤模型、膠質(zhì)瘤干細(xì)胞誘導(dǎo)性惡性腫瘤血管富含膠質(zhì)瘤模型,、術(shù)后炎癥反應(yīng)誘導(dǎo)性膠質(zhì)瘤逆分化模型,、微環(huán)境適應(yīng)性異質(zhì)亞型腫瘤干細(xì)胞分布膠質(zhì)母細(xì)胞瘤模型。并針對這些模型先后開發(fā)了膠質(zhì)瘤干細(xì)胞內(nèi)源性多重信號抑制,、促膠質(zhì)瘤干細(xì)胞分化,、異質(zhì)型惡性膠質(zhì)母細(xì)胞瘤表觀遺傳調(diào)節(jié)因子為靶向的治療方案。今后將開發(fā)膠質(zhì)瘤干細(xì)胞活體追蹤診斷系統(tǒng),，著重針對表觀遺傳調(diào)節(jié)因子,、mRNA修飾、蛋白質(zhì)修飾為靶向的治療方案的研究,。
受教育經(jīng)歷：
1996-2000年,，延邊大學(xué)，學(xué)士,；
2000-2003年,，首爾大學(xué)，碩士,；
2003-2007年,，首爾大學(xué)，博士,；
研究工作經(jīng)歷：
2007-2008年,，首爾大學(xué)，博士后,；
2008-2013年,，高麗大學(xué)，研究教授,；
2013-2017年,，克利夫蘭診所，研究員,；
2014-至今,，溫州醫(yī)科大學(xué)附屬第一醫(yī)院，訪問教授,；
2017-至今,，天津醫(yī)科大學(xué)腫瘤醫(yī)院,，教授
科研論文(SCI)：
共39篇(IF > 229)，第一或通訊14篇(IF > 90)
代表性論文
1. Wang X, Prager BC, Wu Q, Kim LJY, Gimple RC, Shi Y, Yang K, Morton AR, Zhou W, Zhu Z, Obara EAA,
Miller TE, Song A, Lai S, Hubert CG, Jin X, Huang Z, Fang X, Dixit D, Tao W, Zhai K, Chen C, Dong Z,
Zhang G, Dombrowski SM, Hamerlik P, Mack SC, Bao S, Rich JN. Reciprocal Signaling between
Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. Cell Stem Cell.
2018 Apr 5;22(4):514-528. (IF: 23.394) ISSN: 1875-9777.
2. Jin X, Kim L, Wallace LC, Valentim C, Mack S, Lee C, Huang P, Dixit D, Wu Q, Kim HG, Rich JN*.
Targeting Glioma Stem Cells through Combined BMI1 and EZH2 Inhibition. Nature Medicine. 2017 Nov;
23(11): 1352-1362. (IF: 30.357) ISSN: 1078-8956.
3. Jin X, Jin X*, Kim LJY, Dixit D, Jeon HY, Kim EJ, Kim JK, Lee SY, Yin J, Rich JN, Kim H.
Inhibition of ID1-BMPR2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy. Clin
Cancer Res. 2018 Jan 15;24(2):383-394. (IF: 9.619 )ISSN: 1078-0432.第一兼通訊
4. Jin X, Jeon HM, Jin X, Kim EJ, Yin JL, Jeon HY, Sohn YW, Oh SY, Kim JK, Kim SH, Jung JE, Kwak
SW, Tang KF, Xu YS, Rich JN,Kim HG* ID1-Cullin3 axis regulates intracellular SHH and WNT signaling in
glioblastoma stem cells. Cell Report. 2016, 16(6):1629-41 (IF: > 8.358 ) ISSN: 2211-1247.
5. Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q,
Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich JN*.The mitotic kinesin KIF11 is a driver of invasion,
proliferation, and self-renewal in glioblastoma. Sci Transl Med. 2015; 9(304):304ra143. (IF: 15.843)
ISSN: 1946-6234. Citation: 13
6. Jin X, Jin X, Sohn YW, Yin J, Kim SH, Joshi K, Nam DH, Nakano I, Kim H*. Blockade of EGFR signaling
promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3
expression. Cancer Lett. 2013;328(2):235-42. (IF: 6.375) ISSN: 0304-3835. Citation: 19
7. Jin X, Kim SH, Jeon HM, Beck S, Sohn YW, Yin J, Kim JK, Lim YC, Lee JH, Kim SH, Kang SH, Pian
XM, Song MS, Park JB, Chae YS, Chung YG, Lee SH, Choi YJ, Nam DH, Choi YK, Kim H*. Interferon regulatory
factor 7 regulates glioma stem cells via interleukin 6 and Notch signaling. Brain 2012;135(Pt4): 1055-69.
(IF: 10.292) ISSN: 0006-8950. Citation: 35
8. Jin X*, Yin J, Kim SH, Sohn YW, Beck S, Lim YC, Nam DH, Choi YJ, Kim H*. EGFR-AKT-Smad
Signaling Promotes Formation of Glioma Stem-like Cells and Tumor Angiogenesis by ID3-Driven Cytokine Induction.
Cancer Res. 2011; 71(22):7125-34. (IF: 9.329) ISSN: 0008-5472, Citation: 84.第一兼通訊
9. Jin X, Jeon HY, Joo KM, Kim JK, Jin J, Kim SH, Kang BG, Beck S, Lee SJ, Kim JK, Park AK, Park WY,
Choi YJ, Nam DH, Kim H*. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established
by serial intracranial transplantation. Cancer Res. 2011; 71(8): 3066-75. (IF: 9.329) ISSN: 00085472. Citation: 92.
10. Jeon HM, Jin X, Lee JS, Oh SY, Sohn YW, Park HJ, Joo KM, Park WY, Nam DH, DePinho RA, Chin L, Kim H*.
Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling.
Genes Dev. 2008; 22(15): 2028-33. (IF: 10.798) ISSN: 08909369. Citation: 110.
獲獎情況：
2017年,、2012年在韓國BRIC被評為為韓國爭光的科學(xué)家,。2012年被韓國高麗大學(xué)評為BK21生命工程學(xué)院最高研究者獎。2016年被EJC評為杰出審稿人,。
.............................................................................................................
李慧,，研究員，博士生導(dǎo)師
1996年畢業(yè)于南開大學(xué)生物化學(xué)專業(yè),，2005年于天津醫(yī)科大學(xué)獲腫瘤學(xué)博士學(xué)位,。
現(xiàn)任國家腫瘤臨床醫(yī)學(xué)研究中心副主任，天津市腫瘤研究所胃腸腫瘤生物學(xué)研究室主任,。先后入選教育部新世紀(jì)優(yōu)秀人才,、天津市131人才第一層次人選等人才稱號，作為負(fù)責(zé)人獲得天津市131創(chuàng)新團(tuán)隊(duì),，獲第十四屆天津青年科技獎,。兼任中國醫(yī)藥生物技術(shù)協(xié)會理事、中國抗癌協(xié)會青年理事會常務(wù)理事,、中國醫(yī)藥生物技術(shù)協(xié)會醫(yī)藥生物技術(shù)臨床應(yīng)用專業(yè)委員會常委等職務(wù),。
主要從事腫瘤免疫微環(huán)境和胃腸腫瘤發(fā)生發(fā)展機(jī)制研究。主要從事胃腸腫瘤微環(huán)境特征及調(diào)控機(jī)制以及胃癌基因變異特征等方面的研究,。積極探索并發(fā)現(xiàn)腫瘤微環(huán)境中調(diào)節(jié)性T細(xì)胞,、腫瘤相關(guān)巨噬細(xì)胞等的特點(diǎn)及分子調(diào)控機(jī)制,，探索腫瘤免疫微環(huán)境調(diào)控的新機(jī)制,，并為建立調(diào)控策略提高免疫治療效果奠定了基礎(chǔ)；其次,，開展胃癌基因變異特征,、診治分子標(biāo)志物群和預(yù)測模型、PDX動物模型等方面的工作,，并探索其在胃癌精準(zhǔn)治療策略中的應(yīng)用,，提高治療的個(gè)體化、精準(zhǔn)化和治療效果,。作為項(xiàng)目負(fù)責(zé)人先后承擔(dān)國家自然科學(xué)基金項(xiàng)目4項(xiàng),、教育部及天津市科委項(xiàng)目3項(xiàng)；作為研究骨干參與973計(jì)劃課題,、863計(jì)劃課題等國家及省部級重點(diǎn)項(xiàng)目,。以第一完成人獲天津市科技進(jìn)步二等獎1項(xiàng)，作為主要參加者獲得中華醫(yī)學(xué)獎及天津市科技進(jìn)步獎5項(xiàng),。第一或通訊作者發(fā)表SCI收錄論文30余篇,。
.............................................................................................................
Ⅱ級PI 劉立仁
劉立仁,，教授，博士生導(dǎo)師,，2014年引進(jìn)我院工作,。主要從事蛋白泛素化修飾與腫瘤發(fā)生發(fā)展的機(jī)制研究，通過對腫瘤細(xì)胞蛋白泛素化調(diào)控機(jī)制的深入研究,，篩選與胃癌發(fā)生發(fā)展密切相關(guān)的泛素化修飾調(diào)控因子,，研究其功能以及作用的分子機(jī)制，并探討其在胃癌早期診斷,、預(yù)后預(yù)測,、新藥研發(fā)等方面的應(yīng)用價(jià)值。目前承擔(dān)國家重點(diǎn)研發(fā)計(jì)劃（重大慢�,。�,、并主持國家自然科學(xué)基金及天津市自然科學(xué)基金等多項(xiàng)課題。近年在Molecular Cell,、Cell Research,、Journal of Biochemistry等刊物發(fā)表多篇論文。
.............................................................................................................
Ⅱ級PI 李祥春
李祥春,，天津醫(yī)科大學(xué)腫瘤醫(yī)院 腫瘤研究所 公共實(shí)驗(yàn)室,研究員,，教授，博士生導(dǎo)師
2016年畢業(yè)于香港中文大學(xué),，生物信息學(xué)方向,，長期從事腫瘤基因組二代測序數(shù)據(jù)分析和挖掘工作的研究，對腫瘤基因組學(xué)前沿研究方法和思路有深刻理解,。熟練掌握腫瘤基因分析技術(shù)方法：數(shù)據(jù)比對,、突變檢測、結(jié)構(gòu)變異分析,、腫瘤異質(zhì)性分析,、突變特征圖譜分析、驅(qū)動基因篩選,、分子分型和標(biāo)記物篩選和新抗原分析等,。近5年來在國際權(quán)威刊物（Nature、Gut,、PNAS,、Nature Communications、Cancer Research和Molecular Biology and Evolution等）上以第一作者身份共發(fā)表SCI論文8篇,，截至目前一共發(fā)表近20篇SCI論文,。
近5年發(fā)表SCI論文：
1. Xiangchun Li, MY Wang, Meng Yang, Hongji Dai, Baifeng Zhang, Wei Wang, Xinlei Chu, Xin Wang, Hong
Zheng, RuifangNiu, Kexin Chen. A mutational signature associated with alcohol consumption
and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Annals of
Oncology. 2018 Jan 16. (IF: 11.855)
2. William K.K. Wu, Xiangchun Li, Xiansong Wang, Rudin Z.W. Dai, Alfred S.L. Cheng, Maggie H.T. Wang,
Thomas Kwong, Tai C. Chow, Jun Yu, Matthew T.V. Chan, S. H. W. Oncogenes without a neighboring tumor-suppressor
gene are more prone to amplification. MolBiolEvol. (2017). doi:10.1093 (IF: 13)
3. Li, Xiangchun, Wu, W. K. K., Xing, R., Wong, S. H., & Liu, Y. (2016). Distinct subtypes of gastric
cancer defined by molecular characterization include novel mutational signatures with prognostic capability,
Cancer Research, 76(7), 1724–1733. doi:10.1158/0008-5472.CAN-15-2443 (IF: 9.329)
4. Nakatsu, G., Li, Xiangchun, Zhou, H., Sheng, J., Wong, S. H., Wu, W. K. K., ... Sung, J. J. Y.
(2015). Gut mucosal microbiome across stages of colorectal carcinogenesis. Nature Communications, 6, 8727.
doi:10.1038/ncomms9727 (IF: 11.47)
5. Chen, K., Yang, D., Li, Xiangchun, Sun, B., Song, F., Cao, W., ... Gao, Z. (2015). Mutational landscape
of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proceedings of the National
Academy of Sciences, 6(1), 1–6. doi:10.1073/pnas.1422640112 (IF: 9.674)
6. Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li,Xiangchun, ... Zhan, Q. (2014). Identification of genomic
alterations in oesophageal squamous cell cancer. Nature, 509(7498), 91–5. doi:10.1038/nature13176 (IF: 41.456)
7. Yu, J., Wu, W. K. K., Li, Xiangchun, X. X., He, J., Li, X.-X. X., Ng, S. S. M., ... Sung, J. J. Y. (2015).
Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut, 64(4), 636–45.
doi:10.1136/gutjnl- 2013-306620 (IF: 14.66)
8. Song, F., Li,Xiangchun, Song, F., Zhao, Y., & Li, H. (2015). Comparative
genomic analysis reveals bilateral breast cancers are genetically independent. Oncotarget. doi:10.18632/oncotarget.
5569 (IF: 6.359)
9. Li, C., Gao, Z., Li, F., Li, Xiangchun, Sun, Y., Wang, M. M., ... Wei, Q. (2015). Whole Exome
Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in
Chinese Patients with Lung Squamous Cell Carcinoma. Scientific Reports, 5(August), 14237. doi:
10.1038/srep14237 (IF: 5.578)
10. Cao, Y., He, M., Gao, Z., Peng, Y., ...Li, Xiangchun, ... Ning, G. (2014). Activating hotspot L205R
mutation in PRKACA and adrenal Cushing’s syndrome. Science, 344(6186), 913–7. doi:10.1126/science.1249480 (IF: 33.611)
11.Zhang, L., Zhou, Y., Cheng, C., Cui, H., Cheng, ...Li, Xiangchun, ... Cui, Y. (2015). Genomic analyses
reveal mutational signatures and frequently altered genes in esophageal squamous
cell carcinoma. American Journal of Human Genetics, 96(4), 597–611. doi:10.1016/j.ajhg.2015.02.017 (IF: 10.931)
12.Yu, C., Yu, J., Yao, X., Wu, W. K. K., Lu, Y., ... Li,Xiangchun, ... Wang, J. J. (2014). Discovery
of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Research,
24(6), 701–12. doi:10.1038/cr.2014.43 (IF: 12.413)
13.Zhao, Y., Yang, J., Chen, Z., Gao, Z., Zhou, F., Li, Xiangchun, ... He, J. (2014). Identification of
somatic alterations in stage I lung adenocarcinomas by next- generation sequencing. Genes Chromosomes and
Cancer, 53(4), 289–298. doi:10.1002/gcc.22138 (IF: 4.041)
14.Xu, L., Li, X. X., Cai, M., Chen, J., Li, X. X., Wu, W. K. K., ...Li, Xiangchun, ...
Yu, J. (2015). Increased expression of Solute carrier family 12 member 5 via gene
amplification contributes to tumour progression and metastasis and associates with poor
survival in colorectal cancer. Gut, 1–12. doi:10.1136/gutjnl-2014-308257 (IF: 14.66)
15.Liu, L., Xu, Y., He, M., Zhang, M., Cui, F., Lu, L., ...Li, Xiangchun, ... Esteban, M. A. (2014).
Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. Cell Stem Cell,
15(5), 574–588. doi:10.1016/j.stem.2014.09.018 (IF: 22.268)
16.Cheng, C., Zhou, Y., Li, H., Xiong, T., Li, S., Bi, Y., ... Li, Xiangchun, ...
Cui, Y. (2016). Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal
Squamous Cell Carcinoma. The American Journal of Human Genetics, 1–19. doi:10.1016/j.ajhg.2015.12.013 (IF: 10.931)
17.Tsang, D. P. F., Wu, W. K. K., Kang, W., Lee, Y.-Y., Wu, F., Yu, Z., ... Li, Xiangchun, ... Cheng,
A. S. L. (2016). Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates Nuclear
Factor-κB in hepatocellular carcinoma. The Journal of Pathology. doi:10.1002/path.4688 (IF: 7.429)
18.Tang, S., Wu, W. K. K., Li, Xiangchun, Wong, S. H., Wong, N., Chan, M. T. V., ... Yu, J. (2016).
Stratification of Digestive Cancers with Different Pathological Features and Survival
Outcomes by MicroRNA Expression. Scientific Reports, 6(4), 24466. doi:10.1038/srep24466 (IF: 5.578)
.............................................................................................................
馬勇杰，天津醫(yī)科大學(xué)腫瘤醫(yī)院研究所教授,，博士研究生導(dǎo)師
2003年在日本愛媛大學(xué)取得醫(yī)學(xué)博士學(xué)位�,，F(xiàn)擔(dān)任海峽兩岸精準(zhǔn)醫(yī)學(xué)協(xié)會理事,、中國抗癌協(xié)會腫瘤轉(zhuǎn)移委員會青年委員、中國抗癌協(xié)會神經(jīng)腫瘤委員會青年委員,。長期致力于腫瘤發(fā)生發(fā)展過程中的分子機(jī)制及其關(guān)鍵調(diào)控因素的醫(yī)學(xué)研究,。具備豐富的研究經(jīng)驗(yàn)，曾主持國家高科技發(fā)展計(jì)劃973項(xiàng)目子課題以及作為副組長參與863專題項(xiàng)目,，并主持國家自然科學(xué)基金,，作為第一發(fā)明人獲得2項(xiàng)國家授權(quán)專利。在國際期刊和國內(nèi)核心科學(xué)期刊上共發(fā)表論文70余篇,。
Publication: (*corresponding author)
（1）Bo Yang, Haoqing Duan, Wenfeng Cao, Yuhong Guo, Yanxue Liu, Lin Sun1, Jingyi Zhang, Yan Sun*, Yongjie Ma*.
Xp11 translocation renal cell carcinoma and clear cell renal cellcarcinoma with TFE3 strong positive immunostaining:
morphology,immunohistochemistry, and FISH analysis. Modern Pathology. 2019;32(10):1521-1535.
（2）Ying Shao, Wei Chong, Xiaoli Liu, Yun Xu, Huikun Zhang, Qiao Xu, Zhifang Guo, Yawen Zhao,Ming Zhang,
Yongjie Ma*, Feng Gu*. Alternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma
progression. Cell Death and Disease 2019;10(6):431-447.
（3）Zhang H, Yu F,Qin F, Shao Y, Chong W, Guo Z, Liu X, Fu L, Gu F, Ma Y*. Combination of cytoplasmic and nuclear
girdin expression is an independent prognosis factor of breast cancer. FASEB J. 2018, 32(5):2395-2410.
（4）Huikun Zhang, Fengxia Qin, Limin Yang, Jia He, Xiaoli Liu, Ying Shao, Zhifang Guo, Ming Zhang, Wenliang Li, Li Fu,
Feng Gu, Yongjie Ma*. Combination of AQP1 and β-catenin expression is an independent prognosis factor in astrocytoma
patients. Oncotarget. 2017, 8 (59): 99414-99428.
（5）Fengxia Qin, Huikun Zhang, Yong Huang, Limin Yang, Feng Yu, Xiaoli Liu, Li Fu, Feng Gu, Yongjie Ma*. Effect
of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with
chemotherapy. Oncotarget. 2017, 8(67):112060-112075.
（6）Fengxia Qin, Huikun Zhang, Ying Shao, Xiaoli Liu, Limin Yang, Yong Huang, Li Fu*, Feng Gu*, Yongjie Ma*.
Expression of aquaporin1, a water channel protein, in cytoplasmis negatively correlated with prognosis of breast cancer
patients. Oncotarget. 2016;7(7)：8143-8154.
（7）Kun Dai, Fengxia Qin, Huikun Zhang, Xiaoli Liu, Caixia Guo, Ming Zhang, Feng Gu*, Li Fu*, Yongjie Ma*. Low
expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
Oncotarget.2016;7(4)：4770-4784.
（8）Tess Z Griffin, Weiliang Kang, Yongjie Ma*, Ming Zhang*. The HAND Database: a gateway tounderstanding the
role of HIV inHIV-associated neurocognitive disorders. BMC Medical Genomics. 2015;8(1):70.
（9）Feng Gu, Yongjie Ma (co-first author), Jiao Zhang, Fengxia Qin, Li Fu*. Function of Slit/Robo signaling in breast
cancer. Front. Med. 2015;9(4)：431-436.
（10）Fengxia Qin, Huikun Zhang, Li Ma, Xiaoli Liu, Kun Dai, Wenliang Li, Feng Gu*, Li Fu*, Yongjie Ma*. Low Expression
of Slit2 and Robo1is Associated with Poor Prognosisand Brain-specific Metastasis ofBreast Cancer Patients. Scientific
Reports. 2015;5:14430.
（11）Gu F, Zhang H, Qin F, Liu X, Li W, Fu L, Ying G, Li B, Zhang M, Ma Y*.Intersectin1-s, A multidomain adapter
protein, Is essential for malignant glioma proliferation.Glia. 2015;63(9):1595-1605.
（12）Feng Gu, Li Wang, Jia He, Xiaoli Liu, Huikun Zhang, Wenliang Li, Li Fu, Yongjie Ma*. Girdin, an actin-binding
protein, is critical for migration, adhesion, and invasion of human glioblastoma cells. Journal of Neurochemistry.
2014;131(4):457-69.
（13）Ting Ding, Ying Zhou, Kai Sun, Weizhong Jiang, Wenliang Li, Xiaoli Liu, Chunying Tian, Zhihui Li, Guoguang Ying,
Li Fu, Feng Gu, Weidong Li, Yongjie Ma*. Knockdown a water channel protein, aquaporin-4, induced glioblastoma cell
apoptosis. Plos One. 2013;8(8):e66751.
（14）Yongjie Ma, Bingbing Wang, Wenliang Li, Xiaoli Liu, Jing Wang, Ting Ding, Jiao Zhang, Guoguang Ying, Li Fu,
Feng Gu. Intersectin1-s is involved in migration and invasion of human glioma cells. Journal of Neuroscience Research.
2011;89(7):1079-90.
（15）Ting Ding, Yongjie Ma (co-first author), Wenliang Li, Xiaoli Liu, Guoguang Ying, Li Fu, Feng Gu. Role of aquaporin-4
in the regulation of migration and invasion of human glioma cells. International Jounal of Oncology. 2011;38(6):1521-31.
（16）Jing Wang, Li Fu, Feng Gu, Yongjie Ma*. Notch1 is involved in migration and invasion of human breast cancer cells.
Oncology Reports. 2011;26(5):1295-303.
（17）Feng Gu, Juan Wang, Li Fu, Yongjie Ma*. Co-culture with microglia promotes neural stem cells differentiation into
astrocytes. Chinese Medical Journal. 2011;124,(20):3394-98.
（18）Bingbing Wang, De Yang, Gengmei Xing, Baoyun Sun, Xiyin Wei, Hua Guo, Guoguang Ying, Ruifang Niu, Ning Zhang,
Yongjie Ma*. An anti-tumor nanoparticle, [Gd@C82(OH)22]n, induces macrophage activation. Journal of Nanoscience and
Nanotechnology. 2011;11(3):2321-9.
（19）Yongjie Ma, Bingbing Wang, Wenliang Li, Guoguang Ying, Li Fu, Ruifang Niu, Feng Gu. Reduction of intersectin1-s
induced apoptosis of human glioblastoma cells. Brain Research. 2010; 1351:222-228.
（20）Yun Xu, Wenliang Li, Li Fu, Feng Gu, Yongjie Ma*. Slit2/Robo1 signaling in glioma migration and invasion.
Neuroscience Bulletin. 2010, 26(6):474-478.
（21）Jing Wang, Feng Gu, Ting Ding, Xiaoli Liu, Gengmei Xing, Yuliang Zhao, Ning Zhang, Yongjie Ma*.
[Gd@C82(OH)22]n nanoparticles inhibit migration and adhesion of glioblatoma cells. Oncology Letters. 2010;1: 771-775.
（22）Jing Wang, Li Fu, Feng Gu*, Yongjie Ma*. A new protein Girdin in tumor metastasis. Chinese Medical Journal.
2010;123 (13): 1786-1788.
（23）Ting Ding, Li Fu, Feng Gu, Yongjie Ma*. Aquaporin-4 in glioma invasion and an analysis of molecular mechanisms.
Journal of Clinical Neuroscience. 2010;17(11) :1359-1361.
（24）Feng Gu, Yongjie Ma (co-first author), Zuping Zhang, Jinghui Zhao, Hisayuki Kobayashi, Lun Zhang, Li Fu.
Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and Neck squamous cell carcinoma.
Oncology Reports. 2010;23(3):671-676.
（25）Feng Gu, Yongjie Ma (co-first author), Yu Fan, Ronggang Lang, Ting Ding, Xishan Hao, Yun Gong, Hisayuki
Kobayashi, Zhiwei Fang, Li Fu. Synovial sarcoma individual chemotherapy directed by collagen gel droplet embedded
culture drug sensitivity test: A case report. Oncology Letters. 2010;1:885-888.
（26）Hua Guo, Feng Gu, Wenliang Li, Baogang Zhang, Ruifang Niu, Li Fu, Ning Zhang, Yongjie Ma*. Reduction of
PKCzetainhibits migration and invasion of human glioblastoma cells. Journal of Neurochemistry. 2009;109(1): 203-213.
（27）Baogang Zhang, Feng Gu, Chunhua She, Hua Guo, Wenliang Li, Ruifang Niu, Li Fu, Ning Zhang, Yongjie Ma*.
Reduction of Akt2 inhibits migration and invasion of glioma cells. International Journal of Cancer. 2009;125(3):585-595.
（28）Hua Guo, Yongjie Ma (co-first author), Baogang Zhang, Baocun Sun, Ruifang Niu, Guoguang Ying, and Ning Zhang.
Pivotal advance: PKCzeta is required for migration of macrophages. Journal of Leukocyte Biology. 2009;85(6):911-918.
（29）Baogang Zhang, Yongjie Ma (co-first author), Hua Guo, Baocun Sun, Ruifang Niu, Guoguang Ying, Ning Zhang.
Akt2 is required for macrophage Chemotaxis. European Journal of Immunology. 2009;39(3):894-901.
（30）Feng Gu, Li Fu, Yongjie Ma*. Functional analysis of calcium channel-mediated exocytosis in synaptic terminals by
FM imaging technique. Neuroscience Bulletin. 2009;25 (4): 401-405.
（31）Ning Ma, Ruifang Niu, Yongjie Ma*. Intersectin 1: a molecular linker in the central nervous system. Neuroscience
Bulletin. 2008;24: (6)401-405.
（32）Yongjie Ma, Masaya Okamoto, Feng Gu, Kyoko Obata, Tomohiro Matsuyama, Junzo Desaki, Junya Tanaka, Masahiro
Sakanaka. Neuronal distribution of EHSH1/intersectin: a molecular linker between clathrin-mediated endocytosis and
signaling pathways. Journal of Neuroscience Research. 2003;71(4):468-477.
（33）Zhao Li, Ma Yongjie, Gu Feng*, Fu Li. Inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer.
Chin Med J 2014;127 (3):442-447.
（34）Masahiro Sakanaka , Pengxiang Zhu, Bo Zhang, Tongchun Wen, Fang Cao, Yongjien Ma, Keiichi Samukawa, Noriaki
Mitsuda, Junya Tanaka, Makoto Kuramoto, Hidemitsu Uno, Ryuji Hata. Intravenous infusion of dihydroginsenoside Rb1
prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-XL. Journal
of Neurotrauma. 2007;24(6):1037-1054.
（35）Fang Cao, Ryuji Hata, Pengxiang Zhu, Yongjie Ma, Junya Tanaka, Yasushi Hanakawa, Koji Hashimoto, Michio
Niinobe, Kazuaki Yoshikawa, Masahiro Sakanaka. Overexpression of SOCS3 inhibits astrogliogenesis and promotes
maintenance of neural stem cells. Journal of Neurochemistry. 2006;98(2):459-470.
（36）Feng Gu, Ryuji Hata, Yongjie Ma, Masahiro Sakanaka. Suppression of Stat3 promotes neurogenesis in cultured neural
stem cells. Journal of Neuroscience Research. 2005;81(2)163-171.
（37）Tong-Chun Wen, Yasutaka Sadamoto, Junya Tanaka, Peng-Xiang Zhu, Kimihiko Nakata, Yongjie Ma, Ryuji Hata,
Masahiro Sakanaka. Erythropoitin protects neurons against chemical hypoxia and cerebral ischemia injury by up-regulated
Bcl-xl expression. Journal of Neuroscience Research. 2002; 67(6):795-803.
（38）Fumio Morita, Tong-Chun Wen, Junya Tanaka, Ryuji Hata, Junzo Desaki, Kohji Sato, Kimihiko Nakata, Yongjie Ma,
Masahiro Sakanaka. Protective effect of a prosaposin-derived,18-Mer peptide on slowly progressive neuronal
degenerationafter brief ischemia. Journal of Cerebral Blood Flow Metabolism. 2001;21(11):1295-1302.
.............................................................................................................
Ⅱ級PI 牛瑞芳
牛瑞芳,，研究員、教授,、博士生導(dǎo)師,；現(xiàn)任腫瘤研究所副所長、公共實(shí)驗(yàn)室主任
1986年畢業(yè)于南開大學(xué)生物系生物化學(xué)專業(yè),，1989年獲得南開大學(xué)生物化學(xué)碩士學(xué)位,，2012年獲得天津大學(xué)生物醫(yī)學(xué)工程博士學(xué)位。
現(xiàn)為中國抗癌協(xié)會腫瘤標(biāo)志物專業(yè)委員會委員,、中國抗癌協(xié)會分子醫(yī)學(xué)專業(yè)委員會委員,、天津市生物化學(xué)與分子生物學(xué)學(xué)會理事、天津市生物醫(yī)學(xué)工程學(xué)會組織工程專業(yè)委員會委員,，科技部重大專項(xiàng)和國家自然科學(xué)基金項(xiàng)目評審專家,，《中國腫瘤臨床》執(zhí)行編委、《中華腫瘤防治雜志》和《現(xiàn)代儀器與醫(yī)療》雜志編委,。
發(fā)表SCI收錄論文40余篇,，獲5項(xiàng)國家授權(quán)專利，曾獲教育部自然科學(xué)獎和天津市科技進(jìn)步獎多項(xiàng),；先后承擔(dān)科技部“863”項(xiàng)目兩項(xiàng),，國家自然科學(xué)基金國際合作項(xiàng)目1項(xiàng),，主持國家自然科學(xué)基金面上項(xiàng)目4項(xiàng),，天津市科委重點(diǎn)項(xiàng)目2項(xiàng)，天津市教委重點(diǎn)項(xiàng)目1項(xiàng),。
研究方向：
1.基于蛋白質(zhì)組學(xué)和高通量測序等研究方法篩選和鑒定與腫瘤發(fā)生發(fā)展密切相關(guān)的蛋白質(zhì),，并解析相應(yīng)的信號傳導(dǎo)網(wǎng)絡(luò)。
2.聚焦腫瘤多藥耐藥的機(jī)制研究,，探索導(dǎo)致耐藥腫瘤侵襲轉(zhuǎn)移能力增強(qiáng)的分子機(jī)制,，為臨床耐藥腫瘤的治療提供新思路。
3.研究癌細(xì)胞侵襲轉(zhuǎn)移的分子機(jī)制,，解析調(diào)控癌細(xì)胞侵襲轉(zhuǎn)移的關(guān)鍵信號通路,，為臨床轉(zhuǎn)移腫瘤的治療提供新靶點(diǎn),。
近年來主持的研究項(xiàng)目：
1.國家自然科學(xué)基金面上項(xiàng)目(2018/01-2021/12)：TGFβ反式激活EGFR信號通路并促進(jìn)乳腺癌細(xì)胞侵襲轉(zhuǎn)移的分子機(jī)制研究(81772804，55萬元)
2.國家自然科學(xué)基金面上項(xiàng)目(2014/01-2017/12)：Anxa2介導(dǎo)IL-6誘導(dǎo)的SHP2/Erk和JAK2/STAT3信號通路激活并促進(jìn)乳腺癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化的分子機(jī)制研究(81372844,，72萬元)
3.教育部高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金(2014/01-2016/12)：Anxa2介導(dǎo)IL-6信號通路并促進(jìn)乳腺癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化的分子機(jī)制研究(20131202110002,，12萬元)
4. 863計(jì)劃子課題(2012/01-2015/12)：腫瘤蛋白質(zhì)分子標(biāo)志物的研究與開發(fā)(2012AA020206，65萬元)
5.天津市自然科學(xué)基金重點(diǎn)項(xiàng)目(2012/04-2015/03)：Anxa2調(diào)控STAT3活性和乳腺癌細(xì)胞侵襲的作用機(jī)制研究(12JCZDJC24500,，20萬元)
6.國家自然科學(xué)基金面上項(xiàng)目(2011/01-2013/12)：MDR1與Anxa2相互作用調(diào)節(jié)耐藥乳腺癌細(xì)胞侵襲的分子機(jī)制研究(81071731,，31萬元)
7. 863計(jì)劃(2008/01-2010/12)：雙親性復(fù)合靶向控釋納米藥物制劑(2007AA021802，408萬)
近年發(fā)表SCI論文(*通訊作者)：
1. Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, Zhang F*, Niu R*: TGF-beta transactivates EGFR and
facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways.
Molecular oncology 2018, 12(3):305-321.
2. Yuan J, Yang Y, Gao Z, Wang Z, Ji W, Song W, Zhang F*, Niu R*: Tyr23 phosphorylation
of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast
Cancer Res Treat2017, 164(2):327-340.
3. Sun X, Zhang J, Wang Z, Ji W, Tian R, Zhang F*, Niu R*: Shp2 Plays a Critical Role in IL-6-Induced
EMT in Breast Cancer Cells. International journal of molecular sciences 2017, 18(2).
4. Yang Y, Wu N, Wang Z, Zhang F, Tian R, Ji W, Ren X, Niu R*: Rack1 Mediates the Interaction of
P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer
Cells. International journal of molecular sciences 2016, 17(10).
5. Zhang J, Zhang F, Niu R*: Functions of Shp2 in cancer. J Cell Mol Med 2015, 19(9):2075-2083.
6. Zhang F, Wang Z, Yuan J, Wei X, Tian R, Niu R*: RNAi-mediated silencing of Anxa2
inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast
Cancer Res Treat 2015, 153(2):263-275.
7. Zhang F, Wang Z, Fan Y, Xu Q, Ji W, Tian R, Niu R*: Elevated STAT3 Signaling-Mediated Upregulation
of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells. International
journal of molecular sciences 2015, 16(10):24772-24790.
8. Zhang F, Liu Y, Wang Z, Sun X, Yuan J, Wang T, Tian R, Ji W, Yu M, ZhaoY,Niu R*: A novel
Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level.
Mol Cell Endocrinol 2015, 411:75-85.
9. Zhang F, Zhang H, Wang Z, Yu M, Tian R, Ji W, Yang Y, Niu R*: P-glycoprotein associates with Anxa2
and promotes invasion in multidrug resistant breast cancer cells. Biochem Pharmacol 2014, 87(2):292-302.
10. Wu B, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Han J, Niu R*: Up-regulation of Anxa2 gene promotes
proliferation and invasion of breast cancer MCF-7 cells. Cell proliferation 2012, 45(3):189-198.
11. Wang H, Wang S, Liao Z, Zhao P, Su W, Niu R*, Chang J: Folate-targeting magnetic core-shell nanocarriers
for selective drug release and imaging. International journal of pharmaceutics 2012, 430(1-2):342-349.
12. Han J, Zhang F, Yu M, Zhao P, Ji W, Zhang H, Wu B, Wang Y, Niu R*: RNA interference-mediated
silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer
Lett 2012, 321(1):80-88.
.............................................................................................................
Ⅱ級PI 宋豐舉
宋豐舉,，博士,，天津醫(yī)科大學(xué)腫瘤醫(yī)院/腫瘤研究所，副研究員,博士生導(dǎo)師
從事腫瘤流行病學(xué)專業(yè)13年,，近五年期間發(fā)表第一作者或通訊作者SCI論文累計(jì)影響因子超過50,，最高單篇影響因子超過10，發(fā)表非第一作者SCI論文20余篇,。主持多項(xiàng)國家和省部級科研項(xiàng)目,，累計(jì)科研經(jīng)費(fèi)超過500萬元。獲得天津醫(yī)科大學(xué)附屬腫瘤醫(yī)院“十二五”第一批“新世紀(jì)人才”,。2014年獲得天津市131創(chuàng)新型人才稱號,，同年獲得USCACA-NFCR優(yōu)秀青年學(xué)者獎。2014年入選意大利衛(wèi)生部科研項(xiàng)目評審專家,。2016年入選天津市中青年科技創(chuàng)新領(lǐng)軍人才,。先后為多家SCI雜志如BMJ，CARCINOGENESIS,，INT J CANCER,，CANCER EPIDEM BIOMAR，CANCER CAUSE CONTROL等做審稿專家,。
.............................................................................................................
Ⅱ級PI 孫燕
孫燕,，天津醫(yī)科大學(xué)腫瘤醫(yī)院病理科主任醫(yī)師、教授,，博士生導(dǎo)師,，主要從事消化系統(tǒng)腫瘤的病理診斷和研究。堅(jiān)持臨床工作與科學(xué)研究相互促進(jìn)的原則,，并積極推進(jìn)科學(xué)研究的臨床轉(zhuǎn)化,。 主持國家自然科學(xué)基金2項(xiàng)，主持省部級課題2項(xiàng),，在JAMA,、Cancer Cell、Clinical Cancer Research、Journal of Pathology,、Cancer等雜志發(fā)表SCI文章30余篇,，累計(jì)影響因子>200。
被評為天津市“131”創(chuàng)新型人才,、國家人力資源和社會保障部留學(xué)回國擇優(yōu)資助人才,、天津市高校優(yōu)秀青年教師。為中國抗癌協(xié)會病理專業(yè)委員會胃癌中青年學(xué)組委員,、中國抗癌協(xié)會大腸癌專業(yè)委員會遺傳學(xué)組委員,、中國研究型醫(yī)院學(xué)會病理專業(yè)委員會委員、中國醫(yī)促會神經(jīng)內(nèi)分泌腫瘤分會委員,、中國中青年病理精英聯(lián)盟成員,。
.............................................................................................................
Ⅱ級PI 應(yīng)國光
應(yīng)國光，博士,，教授,，PI，博士生導(dǎo)師,。天津市腫瘤研究所副所長,，腫瘤細(xì)胞生物學(xué)實(shí)驗(yàn)室主任。天津市腫瘤防治重點(diǎn)實(shí)驗(yàn)室主任,，天津市醫(yī)學(xué)健康領(lǐng)域重點(diǎn)實(shí)驗(yàn)室創(chuàng)新戰(zhàn)略聯(lián)盟理事長,。畢業(yè)于清華大學(xué)化學(xué)系、都靈大學(xué)醫(yī)學(xué)院和米蘭Mario Negri藥理研究所,。1986-1992年上海生物制品研究所國家科委基因工程中心助研,。2007年任職于天津醫(yī)科大學(xué)附屬腫瘤醫(yī)院。歷年主要學(xué)術(shù)貢獻(xiàn)包括：參與完成國家863計(jì)劃人基因工程產(chǎn)品的中試研究及產(chǎn)業(yè)化開發(fā),，獲國家科技進(jìn)步一,、二等獎�,？寺¤b定T160/SSRP1與cross-form DNA的相互作用,，提出結(jié)構(gòu)識別為特征的基因擴(kuò)增及轉(zhuǎn)錄調(diào)控假說。發(fā)現(xiàn)Nucleolin為Myb原癌基因轉(zhuǎn)錄協(xié)同子以及不同Myb分子的組織特異轉(zhuǎn)錄活性機(jī)制,。發(fā)現(xiàn)FPRL1/FPR2為神經(jīng)細(xì)胞保護(hù)因子Humanin的天然受體,，闡明Humanin抗Aβ的神經(jīng)保護(hù)機(jī)制。最先展開具有特異膜調(diào)控潛能的EHD新基因家族的系統(tǒng)比較與功能研究,，并圍繞膜轉(zhuǎn)運(yùn)機(jī)制對關(guān)鍵受體胞內(nèi)轉(zhuǎn)運(yùn)與細(xì)胞信號傳導(dǎo),、其異變在腫瘤中的生物學(xué)作用及其臨床轉(zhuǎn)化應(yīng)用前景、路線和策略等方面進(jìn)行探索,。學(xué)術(shù)論文四十余篇發(fā)表于The Journal of Biological Chemistry、the Journal of Immunology等國際專業(yè)期刊。
主要獎勵(lì)
1992歐共體瑪麗亞·居里獎學(xué)金
1993中國國家科技進(jìn)步一等獎,，人基因工程a1干擾素的研制,，主要研制者之一
1994意大利腫瘤合作協(xié)會獎學(xué)金
1995中國國家科技進(jìn)步二等獎，人基因工程γ干擾素的研制,、中試生產(chǎn)及臨床應(yīng)用,，主要研制者之一
1995衛(wèi)生部科技進(jìn)步一等獎，基因工程γ干擾素的研制,、中試生產(chǎn)及臨床應(yīng)用,，主要研制者之一
研究基金
2008.1-2010.12 EHD蛋白對ErbB受體的轉(zhuǎn)運(yùn)調(diào)控機(jī)制研究,國家自然科學(xué)基金，主持項(xiàng)目,。
2009.10-2012.9非激素依賴性前列腺癌的蛋白組學(xué)和分子靶向研究,天津市科委CMM-天津合作基金,，合作項(xiàng)目。
2010.1-2014.8 iCSCs侵襲和轉(zhuǎn)移相關(guān)預(yù)警分子篩查及意義研究(腫瘤干細(xì)胞在惡性腫瘤發(fā)生發(fā)展中的作用及機(jī)理研究),，國家973計(jì)劃項(xiàng)目子課題,，合作項(xiàng)目。
2011.1-2013.12膜轉(zhuǎn)運(yùn)調(diào)節(jié)蛋白EHD的核功能及其影響乳腺病變的機(jī)制研究,，國家自然科學(xué)基金,主持項(xiàng)目,。
2012.1-2014.12天津?yàn)I海新區(qū)聯(lián)合攻關(guān)合作項(xiàng)目。
2014.4-2017.3國家腫瘤臨床醫(yī)學(xué)研究中心A類項(xiàng)目, 主持項(xiàng)目,。
2016.10-2018.9腫瘤活細(xì)胞高分辨顯微成像平臺建設(shè) 天津市科委創(chuàng)新平臺與人才專項(xiàng),主持項(xiàng)目,。
2018.1-2021.12 microRNA負(fù)調(diào)控EHD表達(dá)促進(jìn)乳腺腫瘤發(fā)生的機(jī)制研究，國家自然科學(xué)基金,主持項(xiàng)目,。
特約審評
2001- The Journal of Biological Chemistry; International Journal of Pharmacology; International
Journal of Radiation, Oncology and BioPhysics
學(xué)術(shù)兼職
2009-中華醫(yī)學(xué)會醫(yī)學(xué)細(xì)胞生物學(xué)分會委員
2011-中國抗癌協(xié)會腫瘤病因?qū)W分會委員
2011-中國抗癌協(xié)會腫瘤轉(zhuǎn)移分會委員
2011- 《中國腫瘤臨床》副主編
2011- 《Clinical Oncology and Cancer Research》編委
近兩年主要論文
1. Qu Y, Zhang H, Sun W, Han Y, Li S, Qu Y, Ying G*, Ba Y*. MiR-155 promotes gastric cancer growth
and invasion by negatively regulating Transforming Growth Factor Beta Receptor 2. Cancer Sci. 2017 Dec 16.
doi: 10.1111/cas.13472.
2. Si Y, Zhang H, Ning T, Bai M, Wang Y, Yang H, Wang X, Li J, Ying G*, Ba Y*. miR-26a/b Inhibit
Tumor Growth and Angiogenesis by Targeting the HGF-VEGF Axis in Gastric Carcinoma. Cell Physiol
Biochem. 2017;42(4):1670-1683.
3. Wang X, Zhang H, Yang H, Bai M, Ning T, Li S, Li J, Deng T, Ying G*, Ba Y*. Cell-derived
Exosomes as Promising Carriers for Drug Delivery and Targeted Therapy. Curr Cancer Drug Targets. 2017
Jul 10. doi: 10.2174/1568009617666170710120311.
4. Ning T, Peng Z, Li S, Qu Y, Zhang H, Duan J, Wang X, Yang H, Liu R, Deng T, Bai M, Wang Y, Si Y, Zhang L,
Wang X, Ge S, Zhou L, Ying G*, Ba Y*. miR-455 inhibits cell proliferation and migration via negative regulation
of EGFR in human gastric cancer. Oncol Rep. 2017 Jul;38(1):175-182. doi: 10.3892/or.2017.5657.
5. Zhang H, Deng T, Liu R, Bai M, Zhou L, Wang X, Li S, Wang X, Yang H, Li J, Ning T, Huang D, Li H, Zhang L,
Ying G*, Ba Y*. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver
metastasis. Nat Commun. 2017 Apr 10;8:15016. doi: 10.1038/ncomms15016.
6. Zhang L#, Wang Y#, Zhang B, Zhang H, Zhou M, Wei M, Dong Q, Xu Y, Wang Z, Gao L, Qu Y, Shi B, Zhu J,
Yin Y, Chen Y, Sun L, Zhang W, Xu S, Ying G*, Wang C*. Claudin-3 expression increases the malignant
potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activation. Oncotarget. 2017 Apr 4;
8(14):23033-23047.
7. Li S, Zhang H, Ning T, Wang X, Liu R, Yang H, Han Y, Deng T, Zhou L, Zhang L, Bai M, Wang X, Ge S, *Ying G,
*Ba Y. MiR-520b/e Regulates Proliferation and Migration by Simultaneously Targeting EGFR in Gastric Cancer. Cell
Physiol Biochem. 2016, 40(6):1303-1315.
8. Li S, Zhang H, Wang X, Qu Y, Duan J, Liu R, Deng T, Ning T, Zhang L, Bai M, Zhou L, Wang X, Ge S, *Ying G,
*Ba Y. Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. Tumour Biol. 2016,
37(11):15175-15183.
9. Zhu Z#, Du S#, Ding F, Guo S, *Ying G, *Yan Z. Ursolic acid attenuates temozolomide resistance in glioblastoma
cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression. Am J Transl Res. 2016,
8(7):3299-308.
10. Liu H, Li Y, Yang R, *Gao X, *Ying G. pH-Responsive Polyethylene Glycol Monomethyl Ether-ε-Polylysine-G-Poly
(Lactic Acid)-Based Nanoparticles as Protein Delivery Systems. PLoS One. 2016, 11(7):e0159296.
11. Duan J#, Zhang H#, Qu Y#, Deng T, Huang D, Liu R, Zhang L, Bai M, Zhou L, *Ying G, *Ba Y. Onco-miR-130
promotes cell proliferation and migration by targeting TGFβR2 in gastric cancer. Oncotarget. 2016, doi: 10.18632/
oncotarget.9936.
12. Qu Y#, Zhang H#, Duan J#, Liu R, Deng T, Bai M, Huang D, Li H, Ning T, Zhang L, Wang X, Ge S, Zhou L,
Zhong B, *Ying G, *Ba Y. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth
factor-β receptor 2 in gastric cancer. Oncotarget. 2016, doi: 10.18632/oncotarget.8946.
13. Zhang H, Liu R, Deng T, Wang X, Lang H, Qu Y, Duan J, Huang D, *Ying G, *Ba Y. The microRNA-124-iGluR2/3
pathway regulates glucagon release from alpha cells. Oncotarget. 2016, 7(17):24734-43.
14. Zhang H, Bai M, Deng T, Liu R, Wang X, Qu Y, Duan J, Zhang L, Ning T, Ge S, Li H, Zhou L, Liu Y, *Huang D,
*Ying G, *Ba Y. Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric
carcinoma. Cancer Lett. 2016,375(2):331-9.
.............................................................................................................
Ⅱ級PI 于津浦
于津浦,，博士,研究員,博士生導(dǎo)師
研究方向：
1、基于NGS的腫瘤分子診斷,；2,、腫瘤免疫微環(huán)境的調(diào)控；3,、新型腫瘤生物治療技術(shù)開發(fā)
主要學(xué)歷：
1.2005/9–2008/7,，天津醫(yī)科大學(xué)，腫瘤學(xué),，博士,，導(dǎo)師：郝希山
2.1997/9–2000/7，天津醫(yī)科大學(xué),，免疫學(xué),，碩士，導(dǎo)師：閆燕華
3.1992/9–1997/7,，天津醫(yī)科大學(xué),，臨床醫(yī)學(xué)，學(xué)士
研究工作簡歷：
1.2013/11-至今，天津醫(yī)科大學(xué),，腫瘤醫(yī)院,，研究員
2.2008/11-2013/10，天津醫(yī)科大學(xué),，腫瘤醫(yī)院,，副研究員
3.2003/11-2008/10，天津醫(yī)科大學(xué),，腫瘤醫(yī)院,，助理研究員
4.2000/7-2003/10，天津醫(yī)科大學(xué),，腫瘤醫(yī)院,，研究實(shí)習(xí)員
主要論著及出處（近5年）：
1.FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer
cells. Liu P, Zhang R, Yu W, Ye Y, Cheng Y, Han L, Dong L, Chen Y, Wei X, Yu J. Biomaterials. 2017 Dec;149:63
-76. Epub 2017 Sep 28.(通訊作者，IF:8.402)
2.Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via
Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. Jiang M, Chen J, Zhang W, Zhang R, Ye Y,
Liu P, Yu W, Wei F, Ren X, Yu J. Front. Immunol. 2017 Dec;8:1840. (通訊作者,，IF:6.429)
3.Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and
pathological types in solid tumors. Cheng Y, Wang S, Han L, Liu P, Li H, Ren X, Yu J, Hao X. Oncotarget. 2017
Aug 7;8(40):68746-68757. eCollection 2017 Sep 15. (通訊作者,，IF:5.168)
4.Dysregulation of SOCS-Mediated negative Feedback of Cytokine Signaling in Carcinogenesis and its Significance
in Cancer Treatment. Mengmeng Jiang, Wen-wen Zhang, Pengpeng Liu, Wenwen Yu, Ting Liu and Jinpu Yu.
Front Immunol. 2017 Feb 8;8:70.(通訊作者，IF:5.849)
5.Suppression of T cells by myeloid-derived suppressor cells in cancer. Jieying Chen , Yingnan Ye, Pengpeng Liu,
Wenwen Yu, Feng Wei, Hui Li, Jinpu Yu.Hum Immunol. 2017 Feb;78(2):113-119.(通訊作者,，IF:2.157)
6.Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification
positive non-small cell lung cancer: a case report. Peng Wang, Pei Xiao, Yingnan Ye, Pengpeng Liu, Lei Han,
Li Dong, Chunhua She, Jinpu Yu. Cancer Biol Med, 2017 May;14(2):183-186. (通訊作者)
7.NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by
activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. Yingnan Ye, Xinxin Long, Lijie Zhang,
Jieying Chen, Pengpeng Liu, Hui Li,Feng Wei, Wenwen Yu, Xiubao Ren, Jinpu Yu.Oncotarget. 2016 Oct 25;7(43):
70303-70322.（通訊作者,，IF:5.312）
8.BMP signaling and its paradoxical effects in tumorigenesis and dissemination. Lijie Zhang, Yingnan Ye, Xinxin
Long, Pei Xiao, Xiubao Ren and Jinpu Yu.Oncotarget. 2016 Nov 22;7(47):78206-78218.（通訊作者，IF:5.312）
9.Neurotensin, a Novel Messenger to Cross-Link Inflammation and Tumor Invasion via Epithelial-Mesenchymal
Transition Pathway. Yingnan Ye, Pengpeng Liu, Yue Wang, Hui Li, Feng Wei, Yanan Cheng, Lei Han & Jinpu Yu.
Int Rev Immunol. 2016 Jul 3;35(4):340-350.（通訊作者,，IF:4.224）
10.IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways.
Long X, Ye Y, Zhang L, Liu P, Yu W, Wei F, Ren X, Yu J. International Journal of Oncology. 2016 Jan;48(1):5-12.
(通訊作者,，IF:3.094)
11.Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary
Thyroid Cancer. Yu Y, Dong L, Li D, Chuai S , Wu Z, Zheng X, Cheng Y, Han L, Yu J, Gao M .Scientific Reports.
2015 Nov 4;5:16129.(共同通訊作者，IF:4.847)
12.Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing
E-cadherin in oral squamous cell carcinoma. Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W, Liu T,
Wang X, Zhou X, Yu J, Hao X. Int J Oncol. 2015 Jun;46(6):2586-94.(共同通訊作者,，IF：3.094)
13.Long noncoding RNA HOTAIR involvement in cancer. Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W,
Wang X, Zhang L, Yu J, Hao X.Tumour Biol. 2014 Oct;35(10):9531-8.(共同通訊作者,，IF：3.445)
14. Noncanonical NF-κB Activation Mediates STAT3-stimulated IDO Upregulation in Myeloid-Derived Suppressor
Cells in Breast Cancer. Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao H, Yan C, Yan F, Ren X.J Immunol. 2014 Sep 1;
193(5):2574-86. (第一作者/共同通訊作者，IF：5.185)
15. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate
with lymph node metastasis in patients with breast cancer. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C,
Liu J, Ren X. J Immunol. 2013 Apr 1;190(7):3783-97.(第一作者,，IF：5.185)
16. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased
inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse
prognosis in patients. Yu J, Ren X, Chen Y, Liu P, Wei X, Li H, Ying G, Chen K, Winkler H, Hao X. PLoS One.
2013;8(2):e56069.(第一作者,，IF：3.349)
17. IDO? DCs and signalling pathways. Wang Y, Yang BH, Li H, Cao S, Ren XB, Yu JP.Curr Cancer Drug Targets.
2013 Mar;13(3):278-88.(通訊作者，IF：3.412)
承擔(dān)和完成科研項(xiàng)目（近五年）
1,、IL-6/STAT3/SOCS通路調(diào)控乳腺癌髓系來源抑制細(xì)胞（MDSCs）生成和免疫抑制活性的機(jī)制研究,。（國家自然科學(xué)基金面上項(xiàng)目，項(xiàng)目負(fù)責(zé)人,，2015.1至2018.12,，項(xiàng)目經(jīng)費(fèi)75萬元）
2、神經(jīng)降壓素/白介素8（NTS/IL-8）通路調(diào)控炎性微環(huán)境誘導(dǎo)肝細(xì)胞肝癌上皮間質(zhì)轉(zhuǎn)化(EMT)的分子機(jī)制探討,。（國家自然科學(xué)基金面上項(xiàng)目,，項(xiàng)目負(fù)責(zé)人，2013.1至2016.12,，項(xiàng)目經(jīng)費(fèi)65萬元）
3,、STAT3/IDO途徑參與乳腺癌髓系來源抑制細(xì)胞（MDSCs）下調(diào)T細(xì)胞免疫及相關(guān)機(jī)制探討（國家自然科學(xué)基金面上項(xiàng)目,，項(xiàng)目負(fù)責(zé)人，2011.1至2013.12,，項(xiàng)目經(jīng)費(fèi)32萬元）
4,、骨髓來源間充質(zhì)干細(xì)胞在前列腺癌誘導(dǎo)骨重塑中的作用研究（共同項(xiàng)目負(fù)責(zé)人,，2012.5-2014.5,，項(xiàng)目經(jīng)費(fèi)10萬美元）
5、ctDNA測序用于胰腺癌術(shù)后復(fù)發(fā)監(jiān)測和靶向藥物篩選（天津市衛(wèi)生行業(yè)重點(diǎn)攻關(guān)項(xiàng)目,，項(xiàng)目負(fù)責(zé)人,，2016.10至2019.10，項(xiàng)目經(jīng)費(fèi)20萬元）
獲得專利
1,、NK細(xì)胞體外培養(yǎng)方法,，發(fā)明專利，2016年,，ZL 2013 1 0691566.9
獲獎情況
1,、項(xiàng)目名稱：《活化異基因造血干細(xì)胞治療晚期實(shí)體腫瘤的臨床應(yīng)用研究》（2011年 天津市科技進(jìn)步三等獎 第一完成人）
擔(dān)任學(xué)術(shù)職務(wù)（國家二級及以上學(xué)術(shù)團(tuán)體）
1、2016年至今中國抗癌協(xié)會家族遺傳性腫瘤協(xié)作組常委
2,、2013年至今中國醫(yī)藥生物技術(shù)協(xié)會醫(yī)藥生物技術(shù)臨床應(yīng)用專業(yè)委員會常委
3,、2015年至今天津市抗癌協(xié)會靶向治療專業(yè)委員會常委
4、2016年至今中國抗癌協(xié)會甲狀腺癌專業(yè)委員會委員
5,、2016年至今天津市醫(yī)學(xué)會婦科腫瘤分會委員
6,、2013年至今《Cancer Biology & Medicine》雜志編委
7、2014年至今《中國腫瘤臨床》雜志編委
實(shí)驗(yàn)室成員
張 蕊 助理研究員
劉芃芃 技術(shù)員
蔣蒙蒙博士研究生 導(dǎo)師：于津浦
張文文博士研究生 導(dǎo)師：于津浦
寧俊雅博士研究生 導(dǎo)師：于津浦
肖 培碩士研究生 導(dǎo)師：于津浦
張 曉碩士研究生 導(dǎo)師：于津浦
劉丹丹碩士研究生 導(dǎo)師：于津浦
.............................................................................................................
Ⅱ級PI 楊莉莉
楊莉莉,，生物技術(shù)研究室 研究員 博士生導(dǎo)師
2001年畢業(yè)于華北理工大學(xué)醫(yī)學(xué)部,，獲得臨床醫(yī)學(xué)學(xué)士學(xué)位，2006年畢業(yè)于吉林大學(xué)白求恩醫(yī)學(xué)部,，獲得生物化學(xué)與分子生物學(xué)博士學(xué)位,。同年7月來天津醫(yī)科大學(xué)腫瘤醫(yī)院生物技術(shù)研究室工作。2009年11月晉升為副研究員,。2013年3月至2015年3月,，受醫(yī)院委派借調(diào)到國家自然科學(xué)基金委員會醫(yī)學(xué)七處工作，職務(wù)為流動項(xiàng)目主任,。2015年12月晉升為研究員�,，F(xiàn)任天津醫(yī)科大學(xué)腫瘤醫(yī)院生物治療中心生物技術(shù)研究室PI，主要從事腫瘤免疫治療和腫瘤微環(huán)境的相關(guān)基礎(chǔ)研究,。
主要研究方向?yàn)椋海?）從事腫瘤生物治療新方法靶向藥物及新型細(xì)胞治療方法的開發(fā)及應(yīng)用研究,。（2）從轉(zhuǎn)錄水平研究腫瘤發(fā)生發(fā)展的相關(guān)機(jī)制。目前,，主持在研國家自然科學(xué)基金項(xiàng)目2項(xiàng),，主持在研天津市留學(xué)人員擇優(yōu)資助重點(diǎn)項(xiàng)目支持1項(xiàng)和天津市衛(wèi)生行業(yè)重點(diǎn)攻關(guān)項(xiàng)目1項(xiàng),。主持完成天津市科委項(xiàng)目1項(xiàng)，天津市教委項(xiàng)目1項(xiàng),。榮獲天津醫(yī)科大學(xué)腫瘤醫(yī)院高層次創(chuàng)新人才“中青年科研型創(chuàng)新人才”榮譽(yù)稱號,。近幾年，以第一作者或通訊作者發(fā)表SCI論文共10余篇,。研究成果以第一或通訊作者發(fā)表在Leukemia（IF=9.379）,、OncoImmunology（IF=6.283）、Cell Mol Life Sci. （IF=5.856）等國際期刊,。
近幾年發(fā)表主要文章：
Lili Yang, Chunjuan Du, Lei Wu, Jinpu Yu Xiumei An, Wenwen Yu, Shui Cao Hui Li, Xiubao Ren.
Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line, J Cancer, 2017;
8(16): 3287-3295.
Dong W, Wu L, Sun H, Ren X, Epling-Burnette PK, Yang L*. MDS shows a higher expression
of hTERT and alternative splice variants in unactivated T-cells. Oncotarget. 2016 Nov 1;7(44):71904-71914.
doi: 10.18632/oncotarget.12115（IF=5.168,，共同通訊）
Dong W, Ding T, Wu L, Ren X, Epling-Burnette PK, Yang L*. Effect of IL-7 and IL-15
on T cell phenotype in myelodysplastic syndromes, Oncotarget. 2016 May 10;7(19):27479-88. doi: 10.18632/
oncotarget.8459（IF=5.168，共同通訊）
Yang L, Qian Y, Eksioglu EA, Epling-Burnette PK, Wei S. The inflammatory microenvironment in MDS.
Cell Mol Life Sci. 2015 May; 72(10):1959-66. (IF=5.788,，第一作者）
Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K,
Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naïve T-cells in
Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency.
Leukemia. 2013 Apr;27(4):897-906. （IF=11.702,，第一作者）
Dong W, Qian Y, Yang L*. Telomerase, hTERT and splice variants in patients with myelodysplastic
syndromes.Leuk Res. 2014 Jul; 38(7):830-5. (IF=2.501，通訊作者）
Qian Y, Yang L*, Cao S*.Telomeres and telomerase in T cells of tumor immunity. Cell Immunol.
2014; 289 (1-2):63-9. (IF=3.172, 共同通訊）
Yang L, Eksioglu EA, Wei S. hTERT deficiency in naïve T cells affects lymphocyte homeostasis in
myelodysplastic syndrome patients. Oncoimmunology. 2013;2(11):e26329. （IF=7.719,，第一作者）
Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X. Enhanced antitumor effects of DC-activated CIKs to
chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol
Immunother. 2013 Jan;62(1):65-73.. （IF=4.711,，第一作者）
以項(xiàng)目負(fù)責(zé)人主持和在研的科研項(xiàng)目:
國家自然科學(xué)基金面上項(xiàng)目，HMGB1調(diào)控hTERT表達(dá)在肺癌發(fā)生發(fā)展中的作用及研究,，2016.1-2019.12,。（批準(zhǔn)號：81572265,83萬，項(xiàng)目負(fù)責(zé)人,，在研）
國家自然科學(xué)基金面青年項(xiàng)目,，來那度胺抑制CD33-ITIM信號調(diào)節(jié)MDSC免疫抑制活性和治療MDS的分子機(jī)制研究，2016.1-2018.12,。（批準(zhǔn)號：31500736,26.2萬,，項(xiàng)目負(fù)責(zé)人，在研）
天津市衛(wèi)生行業(yè)重點(diǎn)攻關(guān)項(xiàng)目,，CAR-T細(xì)胞治療晚期復(fù)發(fā)難治性B細(xì)胞淋巴瘤的研究,，2015.10-2018.10.（批準(zhǔn)號：15KG145，15萬,，項(xiàng)目負(fù)責(zé)人,，在研）
天津市留學(xué)人員擇優(yōu)資助重點(diǎn)項(xiàng)目，SIRT6介導(dǎo)的端粒表觀遺傳改變在骨髓衰竭性疾病中的作用,，2015 年,。（10萬，項(xiàng)目負(fù)責(zé)人,，在研）
天津市應(yīng)用基礎(chǔ)與前沿技術(shù)研究計(jì)劃項(xiàng)目（天津市科委面上項(xiàng)目）,，PinX1 靶向肺癌干細(xì)胞端粒酶誘導(dǎo)凋亡的實(shí)驗(yàn)研究，2014.4-2017.3.（批準(zhǔn)號：14JCYBJC25500,10萬,，項(xiàng)目負(fù)責(zé)人,，完成）
天津市高等學(xué)�,？萍及l(fā)展基金計(jì)劃項(xiàng)目（天津市教委課題），肺癌T細(xì)胞端粒酶異常表達(dá)對其增殖影響及機(jī)制初探,，2012.12-2015.12.（批準(zhǔn)號：20120110,4萬,，項(xiàng)目負(fù)責(zé)人，完成）
天津市衛(wèi)生局科技基金,，A20和HMGB1雙重調(diào)節(jié)的腫瘤DC疫苗抗腫瘤實(shí)驗(yàn)研究, 2009.4-2011.3.（批準(zhǔn)號：09KZ80,，2萬，項(xiàng)目負(fù)責(zé)人,，完成）
|
